Berliner Boersenzeitung - The scientist rewriting DNA, and the future of medicine

EUR -
AED 4.204786
AFN 72.131522
ALL 95.999785
AMD 432.40092
ANG 2.049533
AOA 1049.907549
ARS 1600.516512
AUD 1.633909
AWG 2.060887
AZN 1.943184
BAM 1.955796
BBD 2.309895
BDT 140.729685
BGN 1.957052
BHD 0.433001
BIF 3404.692377
BMD 1.144937
BND 1.467597
BOB 7.924982
BRL 6.10469
BSD 1.146897
BTN 105.862225
BWP 15.628033
BYN 3.393492
BYR 22440.773758
BZD 2.306495
CAD 1.569761
CDF 2584.123556
CHF 0.90381
CLF 0.026697
CLP 1054.13247
CNY 7.896174
CNH 7.904373
COP 4228.895119
CRC 539.601148
CUC 1.144937
CUP 30.340842
CVE 110.265235
CZK 24.466209
DJF 204.229543
DKK 7.471896
DOP 70.46015
DZD 153.144657
EGP 60.431974
ERN 17.174062
ETB 179.018681
FJD 2.551715
FKP 0.860737
GBP 0.863673
GEL 3.12551
GGP 0.860737
GHS 12.454972
GIP 0.860737
GMD 84.152708
GNF 10054.767863
GTQ 8.795019
GYD 239.939463
HKD 8.963452
HNL 30.358065
HRK 7.534712
HTG 150.375066
HUF 392.446831
IDR 19449.052236
ILS 3.600072
IMP 0.860737
INR 105.821702
IQD 1502.403197
IRR 1513292.432889
ISK 144.20515
JEP 0.860737
JMD 179.950383
JOD 0.811718
JPY 182.703386
KES 148.337757
KGS 100.124438
KHR 4598.96962
KMF 493.468258
KPW 1030.44363
KRW 1715.448554
KWD 0.351988
KYD 0.955702
KZT 561.461195
LAK 24574.94498
LBP 102700.170069
LKR 356.927642
LRD 209.870447
LSL 19.262157
LTL 3.380703
LVL 0.692561
LYD 7.317984
MAD 10.801676
MDL 20.006955
MGA 4762.010134
MKD 61.639593
MMK 2403.69357
MNT 4086.255615
MOP 9.24532
MRU 45.885897
MUR 53.251062
MVR 17.689468
MWK 1988.604232
MXN 20.439555
MYR 4.503092
MZN 73.172957
NAD 19.262241
NGN 1589.046972
NIO 42.20009
NOK 11.164686
NPR 169.37936
NZD 1.970105
OMR 0.443929
PAB 1.146797
PEN 3.954991
PGK 5.014989
PHP 68.684226
PKR 320.228483
PLN 4.271887
PYG 7398.983435
QAR 4.169009
RON 5.095425
RSD 117.37025
RUB 92.411407
RWF 1673.603562
SAR 4.29649
SBD 9.218713
SCR 17.510961
SDG 688.107329
SEK 10.803727
SGD 1.467125
SHP 0.859
SLE 28.107741
SLL 24008.777972
SOS 654.301392
SRD 42.990121
STD 23697.893319
STN 24.499945
SVC 10.035021
SYP 126.544188
SZL 19.255957
THB 37.130895
TJS 10.992623
TMT 4.007281
TND 3.391707
TOP 2.756734
TRY 50.576236
TTD 7.778017
TWD 36.716884
TZS 2982.257478
UAH 50.575008
UGX 4311.990346
USD 1.144937
UYU 46.070098
UZS 13847.908522
VES 506.869099
VND 30103.267553
VUV 135.392596
WST 3.13165
XAF 655.958396
XAG 0.014405
XAU 0.000229
XCD 3.094251
XCG 2.066904
XDR 0.815802
XOF 655.955531
XPF 119.331742
YER 273.125117
ZAR 19.293513
ZMK 10305.812598
ZMW 22.32295
ZWL 368.669387
  • RBGPF

    0.1000

    82.5

    +0.12%

  • RELX

    -0.0400

    34.14

    -0.12%

  • NGG

    0.0900

    90.9

    +0.1%

  • BCC

    0.3800

    70

    +0.54%

  • RYCEF

    -1.1300

    16.12

    -7.01%

  • BCE

    -0.1100

    25.57

    -0.43%

  • GSK

    -0.8900

    53.39

    -1.67%

  • CMSC

    -0.1500

    22.99

    -0.65%

  • CMSD

    -0.1100

    22.99

    -0.48%

  • JRI

    -0.2300

    12.59

    -1.83%

  • RIO

    -2.8700

    87.83

    -3.27%

  • AZN

    -2.6000

    189.9

    -1.37%

  • VOD

    0.1000

    14.41

    +0.69%

  • BTI

    0.0400

    59.93

    +0.07%

  • BP

    0.5100

    42.67

    +1.2%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: Casey ATKINS - Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

(K.Müller--BBZ)